TAM
BPMC

Tiverton Asset Management’s Blueprint Medicines BPMC Stock Holding History

Tiverton Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$542K Hold
7,375
– – 0.02% 384
2019
Q2 		$696K Buy
+7,375
New +$609K 0.02% 319

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tiverton Asset Management's BPMC Position: Q3 2019 in Review

Tiverton Asset Management held its Blueprint Medicines (BPMC) position steady in Q3 2019 at 7,375 shares worth $542K. The position accounts for 0.02% of the portfolio, ranked #384.

Tiverton Asset Management first reported a position in BPMC in Q2 2019 and has held it in 2 quarters since. The position peaked at $696K in Q2 2019. 219 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Tiverton Asset Management held 7,375 shares of Blueprint Medicines worth $542K as of Q3 2019.
  • Tiverton Asset Management left its Blueprint Medicines share count unchanged in Q3 2019.
  • Blueprint Medicines made up 0.02% of Tiverton Asset Management's portfolio in Q3 2019, its #384 holding.
  • Tiverton Asset Management first reported a position in Blueprint Medicines in Q2 2019 and has held it in 2 quarters since.
  • Tiverton Asset Management's Blueprint Medicines position peaked at $696K in Q2 2019.
  • 219 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.